This Article  • References  • Full text PDF  • Send to a friend  • Save in My Folder  • Save to citation manager  • Permissions  Citing Articles  • Citing articles on HighWire  • Contact me when this article is cited  Related Content  • Similar articles in JAMA  Social Bookmarking   What's this?

Valerie Blair, MSc, CStat
The CRC Paediatric and Familial Cancer Research Group Manchester, England

JAMA. 1994;272(13):1004.

	Since this article does not have an abstract, we have provided the first 150 words of the full text PDF and any section headings.

To the Editor.

—In 1991, THE JOURNAL published¹ a meta-analysis on the effects of estrogen replacement therapy on the risk of breast cancer. Data for the analysis were extracted from 18 published case-control studies. Six of these reported relative risks (RRs) associated with ever-use of estrogen replacement therapy for women with and without a family history of breast cancer. Results from these studies were combined and an RR of 3.4 (95% confidence interval [CI], 2.0 to 6.0) was reported in women with a family history, which was significantly greater than in women without (RR, 1.5; CI, 1.2 to 1.7). These results raised a question as to whether estrogen replacement therapy should be given to women with a family history of breast cancer. As this has implications for our local research interests, the methods of the meta-analysis and reported results were examined.

The method of calculating summary RRs used for . . . [Full Text PDF of this Article]

CiteULike    Connotea    Del.icio.us    Digg    Reddit    Technorati    Twitter     What's this?